Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Local ablative therapy for oligometastatic non-small cell lung cancer with actionable mutations: A consensus from Hong Kong SBRT Study Group.

Created on 19 Nov 2026

Authors

Jonathan Shi-Feng Nyaw, Michael Tsz-Yeung Kam, Mary Yuk-Ting Lam, Dennis Kwok-Chuen Leung, Fiona Mei-Ying Lim, Mitchell C Liu, Rico Hing-Ming Hung, Jeffrey Chun-Hin Chan, Venus Wan Yan Lee, Molly S C Li, James Chung-Hang Chow, Xibin Qiu, Andy Kin-Kong Li, Jeffrey C F Lui, James Chung-Man Ho, Michael Kuan-Yew Hsin, Victor Ho-Fun Lee, Calvin S H Ng, Florence Siu-Ting Mok, Winnie Wing-Yan Tin, Ken Ka-Shing Wong, Rina Hui, Feng-Ming Spring Kong, Chi-Leung Chiang, Oscar Siu-Hong Chan

Published in

International journal of radiation oncology, biology, physics. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Oligometastatic non-small cell lung cancer (NSCLC) is increasingly encountered in clinical practice, owing to advances in imaging techniques and the emergence of new therapeutic options. This manuscript presents the outcomes of a meeting of experts from Hong Kong, convened to review the evidence and provide guidance on the use of local ablative therapies (LATs) for patients with oligometastatic NSCLC harboring actionable mutations. The discussion addressed key topics, including the definitions of oligometastatic and oligoprogressive disease, criteria for selecting patients for radiotherapy and other LAT modalities, optimal radiotherapy dosage, and the sequencing and timing of LATs in conjunction with targeted molecular therapies. Guidance was also developed regarding whether to pause or continue systemic treatments during LAT, and the evidence supporting emerging biomarkers in this context was reviewed. Consensus statements were formulated using a modified Delphi approach, and several case examples were presented to illustrate the application of these recommendations in clinical management. The consensus statements from this meeting could provide an important basis for tailoring treatment for patients with NSCLC who have actionable mutations, as well as pointing out key areas to explore in upcoming research.

PMID:
43051603
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement